2015 American Transplant Congress
Molecular and Functional Immune Assays as Non-Invasive Diagnostic Tools to Assess the Risk of Acute Subclinical Rejection After Kidney Transplantation
Subclinical allograft rejection (sc-AR) is still a main cause of allograft loss that can only be assessed through invasive surveillance biopsies. We sought to investigate…2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
1Barnes-Jewish Hospital, St. Louis; 2Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…2015 American Transplant Congress
Alemtuzumab Induction Is Protective Against Acute Rejection in Kidney Recipients With Subtherapeutic Tacrolimus Concentrations
Transplant Surgery, University of North Carolina Hospitals, Chapel Hill, NC.
Purpose: To determine the effect of attaining early therapeutic tacrolimus (TAC) trough concentrations on biopsy-proven acute rejection (BPAR) within 12 months post-transplantation in adult kidney…2015 American Transplant Congress
Toll-Like Receptor 4-Signaling Abrogates Inhibitory Effect of Calcineurin Inhibitor on B-Cells Responding to Blood Group A-Antigens
Transplant Unit, Hiroshima University, Hiroshima, Japan.
Aim: Bacterial infection following ABO-incompatible organ-transplantation is associated with refractory Ab-mediated rejection. Here, we investigated the influence of toll-like receptor (TLR)-signaling, via the binding of…2015 American Transplant Congress
Predicting Graft Loss in a Population of Kidney Transplant Patients Diagnosed With ABMR/TG
ABMR is the main cause of late graft loss in kidney transplants. Our goal was to determine the variables most strongly predictive of graft loss…2015 American Transplant Congress
Eomes-Expressing CD8+ T Cells and Th17 Cells Mediate Costimulatory Blockade-Resistant Allograft Rejection in Mice
The etiology of costimulatory blockade-resistant allograft rejection remains unclear. Therefore, the purpose of this study was to evaluate the responsiveness of distinct CD4+ and CD8+…2015 American Transplant Congress
Upregulation of Heart Transplant IL-33 Is Critical in Cardiac Tissue Repair
Starzl Transplantation Institute, Department of Surgery, Univ of Pittsburgh, Pittsburgh, PA.
Background: IL-33 is tissue-derived cytokine whose primary proposed function is to modulate immune responses when released during injury. Delivery of recombinant IL-33 protects cardiac allografts…2015 American Transplant Congress
Treatment of Subclinical Rejection Identified On Surveillance Biopsy May Prevent the Development of Chronic Alloimmune Injury
Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Surveillance biopsies [SBx] are not universally performed following renal transplantation. In patients in whom protocol biopsies are performed, how best to manage subclinical rejection [SCR]…2015 American Transplant Congress
Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation
BackgroundSeveral studies demonstrated bortezomib therapy for antibody-mediated rejection (AMR) in renal transplants. However, the treatment efficacy according to target antigen or occurrence time of AMR…2015 American Transplant Congress
Incidence and Impact of De Novo Donor-Specific Anti-HLA Antibodies in ABO-Compatible Liver-Transplant Recipients
Background: The incidence and consequences of de novo donor-specific anti-HLA antibodies (DSAs) after liver transplantation (LT) are not well known. Thus, we investigated the incidence,…
- « Previous Page
- 1
- …
- 161
- 162
- 163
- 164
- 165
- …
- 172
- Next Page »